2-Aminoethyl Methyl Sulfone Hydrochloride CAS 104458-24-4 Purity >99.0% (HPLC)

Short Description:

2-Aminoethyl Methyl Sulfone Hydrochloride

CAS: 104458-24-4

Purity: >99.0% (HPLC)

Appearance: White or Off-White Powder

Intermediate of Lapatinib / Lapatinib Ditosylate Monohydrate

Contact: Dr. Alvin Huang     

Mobile/Wechat/WhatsApp: +86-15026746401   

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Lapatinib Intermediates:

Chemical Properties:

Chemical Name 2-Aminoethyl Methyl Sulfone Hydrochloride
Synonyms 2-Aminoethylmethylsulfone Hydrochloride; 2-(Methylsulfonyl)ethanamine Hydrochloride; 2-(Methylsulfonyl)Ethylamine HCl; 2-Aminoethylmethyl Sulfone HCl; Lapatinib Intermediate 1
CAS Number 104458-24-4
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C3H9NO2S·HCl
Molecular Weight 159.63
Melting Point 165.0 to 172.0℃
Stability Hygroscopic
Solubility Soluble in Methanol
Sample  Available
Origin Shanghai, China
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White or Off-White Powder 
Purity / Analysis Method >99.0% (HPLC)
Melting Point 165.0~172.0℃
Loss on Drying <1.00%
Residue on Ignition <0.50%
Total Impurities <1.00%
Heavy Metals (as Pb) <20ppm
Test Standard Enterprise Standard
Usage Intermediate of API (CAS 388082-77-7)

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

www.ruifuchem.com

104458-24-4 - Application:

2-Aminoethyl Methyl Sulfone Hydrochloride (CAS: 104458-24-4) is an intermediate of API (CAS: 388082-77-7). (CAS: 388082-77-7) is a new drug targeted for the treatment of breast cancer developed by GlaxoSmithKline, which was approved for marketing by the US Food and Drug Administration on March 13, 2007. The currently approved indications are advanced mastocarcinoma treated with (CAS: 388082-77-7) and Capecitabine or metastatic breast cancer, and breast cancer patients must be treated first in other first-class drugs. Its trade name is Tykerb in the United States. On December 14, 2007, the European Medicines Agency (EMEA) approved for marketing in Europe, and the trade name is Tyverb. Breast cancer molecular targeted therapy is the treatment for oncogene related with occurrence and development of breast cancer, and for its related expression product. Molecular targeted drugs control the changes of gene expression in the cell through blocking signal transduction of tumor cell or related cell, thereby inhibiting or killing tumor cells.

  • Write your message here and send it to us